Discover WHEN There's Hope on the Horizon The medications we supply are intended for patients with a body mass index (BMI) of 27 or higher, who have at least one weight-related condition, or for patients with a BMI of 30 or higher
Some menstrual changes may be temporary and harmless, but certain symptoms deserve medical attention
SYNERGY-NASH trial: the numbers that stunned hepatologists The SYNERGY-NASH trial tested tirzepatide against placebo in patients with MASH
Choose CJC-1295 with DAC If: You want less frequent injections Convenience is a priority You're focused on anti-aging benefits You don't mind elevated baseline GH Choose CJC-1295 without DAC If: You want natural GH pulsing You're combining with GHRPs (like Ipamorelin) You prefer physiological hormone release You're concerned about desensitization Dosing Protocols CJC-1295 with DAC CJC-1295 without DAC The Popular CJC-1295/Ipamorelin Stack This is the most common peptide combination for GH optimization: Why It Works CJC-1295 (no DAC) amplifies GH release Ipamorelin provides the trigger pulse Synergistic effect = stronger GH response Maintains natural pulsatile pattern Protocol Morning (fasted): CJC-1295: 100mcg Ipamorelin: 100mcg Post-workout: CJC-1295: 100mcg Ipamorelin: 100mcg Before bed: CJC-1295: 100mcg Ipamorelin: 100mcg What to Expect With DAC (Timeline) Week 1-2: Better sleep, mild water retention Week 4-8: Improved recovery, subtle fat loss Week 12+: Body composition changes Without DAC (Timeline) Days 1-7: Improved sleep quality Week 2-4: Enhanced recovery Week 6-12: Visible body composition changes Safety Considerations Common Side Effects Water retention (especially with DAC) Tingling/numbness (carpal tunnel-like) Fatigue initially Injection site reactions Precautions Start with lower doses to assess tolerance Stay well-hydrated Monitor blood glucose if diabetic Cycle usage appropriately Frequently Asked Questions Q: Can I mix DAC and non-DAC versions
The Ministry of Food and Drug Safety (MFDS) is closely watching whether the recent reports about the possibility of glucagon-like peptide 1 (GLP-1) treatments causing suicidal or self-harming thoughts will also affect Korean patients
Significant results are typically observed after 12 to 16 weeks, with continued improvements over the course of the treatment
